HUTCHMED’s Fanregratinib Wins China NMPA Approval for FGFR2+ Intrahepatic Cholangiocarcinoma (ICC)
HUTCHMED has secured conditional approval from China’s National Medical Products Administration (NMPA) for fanregratinib (HMPL-453), providing a new targeted treatment option for patients with FGFR2-altered intrahepatic cholangiocarcinoma (ICC).
The NMPA approved fanregratinib (ATLED®) for adult patients with advanced, metastatic or unresectable ICC harboring FGFR2 fusions or rearrangements who have previously received systemic therapy. The drug will be marketed in China under the brand name ATLED®.
The approval marks another expansion of precision oncology options in China and specifically addresses a molecularly defined subgroup of cholangiocarcinoma patients with limited treatment options after systemic therapy.
A Selective FGFR1/2/3 Inhibitor
Fanregratinib is a novel, orally administered, highly selective and potent inhibitor of fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3.
Aberrant FGFR signaling can promote tumor-cell proliferation, angiogenesis and resistance to anticancer therapy. FGFR2 fusions and rearrangements are particularly relevant in intrahepatic cholangiocarcinoma, where they represent an actionable oncogenic driver.
According to HUTCHMED, approximately 10%–15% of patients with ICC globally harbor FGFR2 fusions or rearrangements, creating a genetically defined population potentially amenable to FGFR-targeted therapy. ICC itself is an aggressive malignancy originating from the intrahepatic biliary epithelium and is the second-most-common primary liver cancer after hepatocellular carcinoma. (investegate.co.uk)
Phase II Study Delivers 42.5% Response Rate
The NMPA approval was supported by the registration cohort of the single-arm, multicenter, open-label Phase II/IIIb study NCT04353375, conducted across 53 sites in China. ClinicalTrials.gov study NCT04353375
The Phase II registration cohort enrolled approximately 87 patients with locally advanced unresectable or metastatic ICC harboring FGFR2 fusions or rearrangements following failure of or intolerance to at least one previous systemic therapy. Patients received fanregratinib tartrate at 300 mg orally once daily for 14 days followed by seven days off treatment in each 21-day cycle. (clinicaltrials.gov)
The study met its primary endpoint, with an Independent Review Committee-assessed objective response rate (ORR) of 42.5% (95% CI: 30.0%–53.6%).
Key efficacy findings included:
- ORR: 42.5%
- Disease control rate (DCR): 83.9%
- Median time to response: 1.4 months
- Median duration of response (DOR): 6.9 months
- Median progression-free survival (PFS): 6.9 months
- Median overall survival (OS): 16.6 months
The efficacy results were presented at the ESMO Gastrointestinal Cancers Congress 2026. All patients in the registration study had previously received chemotherapy, while approximately 72% had also received immunotherapy, underscoring the heavily pretreated nature of the study population. (globenewswire.com)
Safety data previously disclosed by HUTCHMED showed that treatment discontinuation due to drug-related adverse events occurred in 2.2% of patients, with no treatment-related deaths reported.
Conditional Approval Followed Priority Review
Fanregratinib had already received regulatory momentum in China before the latest decision. HUTCHMED announced in December 2025 that the NMPA had accepted the drug’s New Drug Application and granted it Priority Review for this indication. HUTCHMED’s December 2025 NDA announcement
The August 2026 conditional approval now allows HUTCHMED to commercialize fanregratinib for eligible FGFR2 fusion/rearrangement-positive ICC patients while additional confirmatory evidence is generated.
Importantly, HUTCHMED said the Phase IIIb portion of NCT04353375 will serve as the confirmatory study to further validate the clinical benefit and safety of fanregratinib. Enrollment in that cohort began in January 2026. (investegate.co.uk)
Expanding the Targeted-Therapy Landscape in Cholangiocarcinoma
FGFR2 has emerged as one of the most clinically validated molecular targets in cholangiocarcinoma. Because FGFR2 fusions and rearrangements occur predominantly in intrahepatic disease, molecular profiling has become increasingly important for identifying patients who could benefit from FGFR inhibition.
Fanregratinib’s approval adds another precision-medicine option for this population in China. Its 42.5% ORR and 16.6-month median OS in previously treated patients provide evidence of clinically meaningful antitumor activity, although the pivotal registration dataset comes from a single-arm study and will require confirmation through the ongoing Phase IIIb program.
For HUTCHMED, the approval also expands the company’s commercial oncology portfolio in China. The company retains worldwide rights to fanregratinib, potentially leaving opportunities for further development and commercialization outside China. (investegate.co.uk)
References
- HUTCHMED. HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma. August 28, 2026. Read the announcement
- HUTCHMED. HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026. June 25, 2026. Read the Phase II announcement
- ClinicalTrials.gov. HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma — NCT04353375. View the clinical trial record
- HUTCHMED. HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma. December 29, 2025. Read the NDA announcement
- U.S. Securities and Exchange Commission. HUTCHMED Phase II fanregratinib clinical-data announcement. June 25, 2026. View the SEC filing
